Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 812 results for "gilead sciences"

Expect Gilead Sciences To Outperform

Summary Fair target price is more than $125 per share. Sovaldi has a potential market of 200 million, worldwide. Political Risks are biggest threat. Target Price The author sets a target price for Gilead Sciences (NASDAQ: GILD ) common stock ... Seeking Alpha, 2 hours ago

237 images for gilead sciences

American Banking News, 3 days ago, 3 days ago
Jutia Group, 3 days ago
BusinessWeek, 4 days ago
WANE-TV, 3 days ago
CNBC, 5 days ago
One News Page United Kingdom, 4 days ago
Waynesville Daily Guide, 3 days ago, 1 week ago
MSN Money, 1 week ago

Gilead Sciences Posts 2Q 2014 Financial Results

Gilead Sciences has reported its results of operations for the quarter ended June 30. In its release on July 23, the company noted that total revenues for the second quarter of 2014 increased to $6.53 billion compared to $2.77 billion for the second ...
 Individual.com15 hours ago Why Im Bullish On Gilead Sciences, Inc. (GILD)  Minyanville4 hours ago Gilead Sciences maakt financiële resultaten tweede kwartaal 2014 bekend  Business Wire1 day ago FDA approves Gilead Sciences Zydelig for three types of blood cancers  Pharmaceutical Technology1 day ago

Hepatitis C medicine being imported for Rs 1 crore

Even as a controversy rages on globally over the eye-popping price of US firm Gilead Science’s hepatitis C drug at $1,000 a pill, Indian patients have already begun importing the medicine from countries like Canada spending, in some cases, up to Rs 1 crore.
 Times of India19 hours ago Gilead Sciences : Pricey Drug for Hepatitis C Brings Loud Criticism from Activists  4 Traders10 hours ago
Bio Spectrum Asia

GILEAD SCIENCES : Mpp-gilead pact on hiv drug is an opportunity for indian pharma companies

The agreement between Medicine Patent Pool (MPP) and Gilead Sciences of the US on HIV drug is expected to provide an opportunity for Indian pharmaceutical companies. Manufacturers in India can develop generic versions of tenofovir ...
 4 Traders14 hours ago Gilead allows sublicense of HIV drug to generic firms  Bio Spectrum Asia3 days ago MPP-GILEAD PACT ON HIV DRUG IS AN OPPORTUNITY FOR INDIAN PHARMA COMPANIES  Pharmacy Choice14 hours ago

Gilead Sciences (GILD) Approaches New Upside Target of $91.85

(SmarTrend(R) News Watch via COMTEX) -- Gilead Sciences (NASDAQ:GILD) has opened bullishly above the pivot of $89.77 today and has reached the first level of resistance at $90.85. Investors may be interested in a cross of the next upside pivot ...
 TradingCharts.com6 hours ago Watch for Shares of Gilead Sciences (GILD) to Approach Resistance at $91.56  Individual.com4 days ago

Gilead Sciences gibt Finanzergebnisse für zweites Quartal 2014 bekannt

FOSTER CITY, Kalifornien (USA)--( BUSINESS WIRE )--Das Unternehmen Gilead Sciences, Inc. (Nasdaq: GILD), hat heute seine Betriebsergebnisse für das am 30. Juni 2014 beendete Quartal bekannt gegeben. Der Gesamtumsatz im zweiten Quartal ...
 Business Wire1 day ago
Irish Examiner

Gilead profit more than quadruples on hep C drug

Gilead Sciences Inc. on Wednesday reported profit that more than quadrupled in its second quarter, topping analysts' expectations on sales of its new breakthrough drug for hepatitis C. The company's performance was driven by explosive growth of ...
 Bioscience Technology Online4 days ago Gilead Sciences - Sovaldi Momentum Continues, Appeal Remains  Seeking Alpha4 days ago Gilead beats forecasts as Sovaldi sales soar24-07-2014  Pharma Letter3 days ago Gilead Sciences Beats Street and Sees Sovaldi Sales Double  TheStreet.com4 days ago

Gilead Crushes Q2 Earnings Estimates as Sovaldi Sales Soar

There is no holding back Gilead Sciences ( GILD ) hepatitis C virus (:HCV) drug Sovaldi. The drug continued its exceptional performance in the second quarter of 2014, helping the company to beat the Zacks Consensus Estimate on both revenues and ...
 Yahoo! Finance4 days ago Gilead beat Street estimates as Sovaldi sales soar  CNBC5 days ago Gilead: Sovaldi Delivers Q2 Product Sales Of $3.5B... Enough Said  Seeking Alpha4 days ago Gilead Sciences Should Report $4B In Sovaldi Sales In Q2'14  Seeking Alpha6 days ago

Miracle cures spur demand for access to Gilead's $1,000 hepatitis pill

The powerful new hepatitis C drug that sent Gilead Science's sales soaring this year is doing the same for the hopes of millions of patients. Sandra Cabrera and Ted Tabor both suffered devastating damage from hepatitis C. After just weeks of ...
 SiliconValley.com2 days ago Gileads $1000-a-pill hepatitis C drug breaks records drives Q2 profit  Big News Network4 days ago $1,000-A-Pill Hepatitis C Drug Boosts Gilead's Fortunes  Kaiser Health News4 days ago Biz Break: Gilead raking in massive cash from hepatitis C drug Sovaldi  SiliconValley.com4 days ago

Biogen, Gilead Crush Earnings Estimates On Hot Drugs

Big-cap biotech leaders Biogen Idec (NASDAQ: BIIB ) and Gilead Sciences (NASDAQ: GILD ) easily beat second-quarter earnings estimates and received product approvals Wednesday, but their stocks reacted very differently. Biogenearnings rose 52% vs.
 Investor's Business Daily4 days ago Biogen, Gilead Earnings Crush Q2 Estimates  Yahoo! Finance4 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - gilead sciences
Get updated on latest news & your favorite topics right in your inbox!
More     Less